The two stocks have been trending in different directions for months. Here's what that says about the broader market.
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
1d
Com impulso de inteligência artificial, as ações da desenvolvedora de software alemã SAP dispararam, elevando seu valor de ...
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...
German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market ...
O novo escritório tem como objetivo promover a sustentabilidade no turismo e atrair investimentos para o setor. Primeiro Escritório Regional da ONU Turismo nas Américas e Caribe é aberto no Rio de ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
The agreement covering Zealand's compound petrelintide, signals renewed efforts by Roche to catch up with obesity market leaders Novo Nordisk and Eli Lilly. Under the accord, Zealand will receive ...
Novo Nordisk launched a direct-to-consumer program last week to sell Wegovy at a reduced price for people who are uninsured or insured on commercial plans that don't cover the obesity drug. Through ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more: New trial data showed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback